UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$234M |
| 2 |
Home Depot
HD
|
+$214M |
| 3 |
Intercontinental Exchange
ICE
|
+$206M |
| 4 |
TJX Companies
TJX
|
+$129M |
| 5 |
BorgWarner
BWA
|
+$122M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$227M |
| 2 |
DFS
Discover Financial Services
DFS
|
+$212M |
| 3 |
Mohawk Industries
MHK
|
+$137M |
| 4 |
Liberty Global Class A
LBTYA
|
+$114M |
| 5 |
Freeport-McMoran
FCX
|
+$112M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 14.05% |
| 2 | Technology | 13.96% |
| 3 | Financials | 13.95% |
| 4 | Industrials | 9.13% |
| 5 | Energy | 8.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
901
MacroGenics
MGNX
$253M
| $7.42M | 0.01% |
341,717
-38,984
| -10% | -$820K |
|
902
Jazz Pharmaceuticals
JAZZ
$15.9B
| $7.38M | 0.01% |
50,198
+2,800
| +6% | +$388K |
|
|
X
903
DELISTED
US Steel
X
| $7.38M | 0.01% |
283,370
+1,100
| +0.4% | +$28.1K |
|
|
MTEM
904
DELISTED
Molecular Templates, Inc.
MTEM
| $7.37M | 0.01% |
11,281
| – | – |
|
|
N
905
DELISTED
Netsuite Inc
N
| $7.36M | 0.01% |
84,726
+27,653
| +48% | +$2.23M |
|
906
Telkom Indonesia
TLK
$15.1B
| $7.34M | 0.01% |
352,600
+31,800
| +10% | +$658K |
|
907
Omega Healthcare
OHI
$14.5B
| $7.31M | 0.01% |
198,292
+7,500
| +4% | +$268K |
|
908
Tenet Healthcare
THC
$20.1B
| $7.29M | 0.01% |
155,286
+200
| +0.1% | +$9.04K |
|
909
Telefônica Brasil
VIV
$19.9B
| $7.27M | 0.01% |
354,600
-28,300
| -7% | -$584K |
|
910
Petrobras
PBR
$121B
| $7.27M | 0.01% |
496,995
-12,400
| -2% | -$181K |
|
|
EPZM
911
DELISTED
Epizyme, Inc
EPZM
| $7.25M | 0.01% |
232,968
-16,897
| -7% | -$398K |
|
912
Woodward
WWD
$22B
| $7.22M | 0.01% |
143,798
-13,800
| -9% | -$629K |
|
|
FL
913
DELISTED
Foot Locker
FL
| $7.18M | 0.01% |
141,582
-135,707
| -49% | -$6.49M |
|
914
iShares Core S&P Mid-Cap ETF
IJH
$126B
| $7.16M | 0.01% |
250,235
-35,485
| -12% | -$975K |
|
915
Revvity
RVTY
$12.4B
| $7.11M | 0.01% |
151,760
+1,200
| +0.8% | +$53.9K |
|
916
Texas Capital Bancshares
TCBI
$4.44B
| $7.07M | 0.01% |
131,013
+25,927
| +25% | +$1.45M |
|
|
TIME
917
DELISTED
Time Inc.
TIME
| $7.05M | 0.01% |
+290,975
| New | +$6.81M |
|
918
Theravance Biopharma
TBPH
$874M
| $7.04M | 0.01% |
+220,912
| New | +$6.65M |
|
919
Ryder
R
$10.3B
| $7.04M | 0.01% |
79,936
+800
| +1% | +$67K |
|
920
Vale
VALE
$63.3B
| $7.03M | 0.01% |
531,027
-26,093
| -5% | -$352K |
|
921
IDEX
IEX
$17.4B
| $7M | 0.01% |
86,728
-700
| -0.8% | -$52.9K |
|
|
KRA
922
DELISTED
Kraton Corporation
KRA
| $6.96M | 0.01% |
310,699
+54,000
| +21% | +$1.38M |
|
923
Vanguard Russell 2000 ETF
VTWO
$17.9B
| $6.94M | 0.01% |
146,106
+37,790
| +35% | +$1.72M |
|
924
Rigel Pharmaceuticals
RIGL
$725M
| $6.9M | 0.01% |
190,020
| – | – |
|
925
Pacira BioSciences
PCRX
$1.06B
| $6.87M | 0.01% |
74,799
-6,600
| -8% | -$503K |
|
Similar funds
UBS AM's Q2 2014 Portfolio in Review
As of Q2 2014, UBS AM held 2,651 positions worth $99B, up 5.7% from $93.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
UBS AM's Q2 2014 filing shows 81 new, 1,135 increased, 556 reduced and 97 closed positions. Its largest new stake was Sabre: 3,529,400 shares worth $70.8M. The largest sale was Allergan Inc, an estimated $227M.
By sector, the portfolio is most concentrated in Healthcare at 14% of assets, down from 14% a quarter earlier, followed by Technology and Financials.
- UBS AM's largest Q2 2014 buy was Sabre: 3,529,400 shares worth $70.8M.
- UBS AM added most to Thermo Fisher Scientific in Q2 2014, an estimated $234M increase.
- UBS AM's biggest Q2 2014 reduction was Allergan Inc, cutting an estimated $227M.
- UBS AM fully exited Freeport-McMoran in Q2 2014, selling an estimated $112M.
- UBS AM's ten largest holdings make up 14% of its $99B portfolio in Q2 2014.
- UBS AM opened 81 new positions and closed 97 in Q2 2014.
- UBS AM's portfolio value rose 5.7% quarter-over-quarter to $99B.
Based on UBS AM's 13F filing for Q2 2014, filed 13 Aug 2014.